La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Aadi Bioscience Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Dave Lennon

Amministratore delegato

US$2.1m

Compenso totale

Percentuale dello stipendio del CEO	7.5%
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	2.6yrs
Durata media del Consiglio di amministrazione	3.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Jul 03

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Jul 02

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

May 10

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dave Lennon rispetto agli utili di Aadi Bioscience?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$69m
Dec 31 2023	US$2m	US$160k	-US$66m

Compensazione vs Mercato: La retribuzione totale di Dave ($USD 2.14M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Dave con le performance aziendali.

AMMINISTRATORE DELEGATO

Dave Lennon (53 yo)

less than a year

Mandato

US$2,135,687

Compensazione

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Neil Desai	Founder & Executive Chairman	12.9yrs	US$2.16m	7.36% $ 3.5m
David Lennon	President	less than a year	US$2.14m	Nessun dato
Scott Giacobello	CFO, Treasurer	2.8yrs	US$1.97m	0% $ 0
Loretta Itri	Chief Medical Officer	2.9yrs	US$1.48m	0.012% $ 5.8k
Stephen Rodin	Senior VP of Legal & General Counsel	2.6yrs	Nessun dato	Nessun dato
Raymond Steitz	Senior VP of Human Resources & Chief Human Resources Officer	2.3yrs	Nessun dato	Nessun dato
Bryan Ball	Chief Technical Operations Officer	2.1yrs	Nessun dato	0.41% $ 193.0k

2.6yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di AADI è considerato esperto (durata media dell'incarico 2.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Neil Desai	Founder & Executive Chairman	12.9yrs	US$2.16m	7.36% $ 3.5m
David Lennon	President	less than a year	US$2.14m	Nessun dato
Caley Castelein	Independent Chairman of the Board	3.1yrs	US$258.91k	0.080% $ 38.0k
Emma Reeve	Independent Director	3yrs	US$240.91k	0% $ 0
Anupam Dalal	Independent Director	3.1yrs	US$235.91k	0.0046% $ 2.2k
Karin Hehenberger	Independent Director	3.1yrs	US$227.41k	0% $ 0
Richard Maroun	Independent Director	7.6yrs	US$240.91k	0% $ 0
Mohammad Hirmand	Independent Director	1.5yrs	US$345.60k	0% $ 0
Behzad Aghazadeh	Independent Director	3.1yrs	US$225.41k	0% $ 0

3.1yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AADI sono considerati esperti (durata media dell'incarico 3 anni).

Aadi Bioscience Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Founder & Executive Chairman notifies of intention to sell stock

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Founder notifies of intention to sell stock

Recent updates

Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce

Aadi Bioscience Provides PRECISION1 Trial Updates

Consensus estimates of losses per share improve by 12%

Price target decreased by 14% to US$10.00

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index

Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop

Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?

Founder & Executive Chairman notifies of intention to sell stock

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Consensus revenue estimates decrease by 14%, EPS upgraded

Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)

New minor risk - Profitability

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Founder notifies of intention to sell stock

Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Price target decreased by 67% to US$11.67

Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Founder notifies of intention to sell stock

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

New minor risk - Share price stability

Aadi Bioscience, Inc. Announces Chief Executive Officer Changes

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Founder notifies of intention to sell stock

Consensus EPS estimates fall by 10%

Second quarter 2023 earnings: EPS misses analyst expectations

Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$38.75

First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022)

Founder notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc. Announces Management Changes

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023

Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting

Consensus revenue estimates increase by 112%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

High number of new directors

Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

Full year 2021 earnings: EPS and revenues exceed analyst expectations